Hep C Treatment - Valeant Shares Advance on Review of Drug

Valeant Shares Advance on Review of Drug
AP via Newsday - is a treatment for adult patients suffering from chronic hepatitis C viral infections with compensated liver disease

MIGENIX initiates enrolment in Phase IIb HCV study of celgosivir+Pegetron
InPharm.com - Celgosivir is a first-in-class, orally-administered, alpha glucosidase 1 inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. Results of the study are anticipated in mid-2006.

MIGENIX Inc. (MGI.TO) Initiates Enrollment In Phase IIb Hepatitis C Clinical Study Of Celgosivir In Combinatio
BioSpace - 1 inhibitor, in development for the treatment of chronic hepatitis C virus (HCV) infections the success of treatment for patients suffering from chronic hepatitis C infections

Canadian Study on Hepatitis C Treatment Based on Patient Weight Showed Consistent Results
AXcess News - In the U.S. weight does not vary the amount of drugs prescribed.Considering the pharmeceutical tactics Shering-Pough practices at U.S. REBETOL (ribavirin, USP) used in the treatment of chronic hepatitis C, sponsored a study in Canada that showed